Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The autophagy-lysosome machinery refers to the coordinated network of proteins, molecular complexes, and organelles responsible for intracellular degradation and recycling of cellular components through autophagy. This process involves the formation of autophagosomes, which encapsulate cytoplasmic material and then fuse with lysosomes for degradation. The lysosomal compartment contains hydrolytic enzymes that break down proteins, lipids, and organelles, enabling cellular adaptation to stress, maintenance of homeostasis, and removal of damaged or harmful material. Dysregulation of this system is implicated in various diseases, including neurodegeneration, cancer, and immune disorders[1][2][3][5][7].
Inhibition of lysosomal acidification (e.g., chloroquine, bafilomycin A1); Induction of autophagy (e.g., rapamycin via mTOR inhibition); Modulation of autophagosome-lysosome fusion; Inhibition of autophagy by blocking autophagosome maturation
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Autophagy-lysosome machinery (null).